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Currently, our knowledge on the progression of osteoporosis and its determinants is limited in
patients with chronic obstructive pulmonary disease (COPD). Bone mineral density generally
remains stable in patients with COPD over a period of 3 years. Nevertheless, the progression
of vertebral fractures was not assessed, while an increase of vertebral fractures over time
may be reasonable.
Aims of the current study were to determine the percentage of newly diagnosed osteopo-
rotic patients after a follow up of 3 years and to identify baseline risk factors for the progres-
sion of osteoporosis in COPD.
Clinically stable COPD outpatients were included. Lung function parameters, body composi-
tion measures, six minute walk distance, DXA-scan and X-spine were assessed at baseline and
repeated after 3 years.
Prevalence of osteoporosis in COPD patients increased from 47% to 61% in 3 years mostly due
to an increase of vertebral fractures. Lower baseline T-score at the trochanter independently
increased the risk for the development of osteoporosis. Additionally, baseline vitamin D defi-
ciency increased this risk 7.5-fold.ospital Eindhoven, Department of Respiratory Medicine, Michelangelolaan 2, 5623 GS Eindhoven,
9; fax: þ31 402435149.
rsatel.nl, lidwien.verboom@cze.nl (L. Graat-Verboom).
2 Elsevier Ltd. All rights reserved.
862 L. Graat-Verboom et al.In conclusion, the prevalence of osteoporosis increased over a 3-year period in patients with
COPD. Baseline risk factors for the development of osteoporosis are osteopenia at the
trochanter and vitamin D deficiency.
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Chronic Obstructive Pulmonary Disease (COPD) is charac-
terized by a progressive not fully reversible airflow limita-
tion.1 Besides this pulmonary component significant extra-
pulmonary effects are to be considered,2,3 including oste-
oporosis. Indeed, COPD patients have a higher prevalence
of osteoporosis than healthy elderly subjects.4,5
Osteoporosis is characterized by a decreased bone
mineral density (BMD) and/or changes of the micro-
architecture, resulting in an increased fragility of bones
with an increased fracture risk as a consequence.6 Local
dual energy absorptiometry (DXA)-scans measure BMD of
the hip and the lumbar spine. Generally this is considered
to be the gold standard to assess osteoporosis.6,7 However,
(non-symptomatic) vertebral fractures can be present in
COPD patients with a normal BMD on DXA-scan.8,9 There-
fore, the combination of local DXA-scans and the assess-
ment of vertebral fractures using X-ray should be used to
diagnose osteoporosis in patients with COPD.8
Our knowledge on the progression of osteoporosis in
COPD is currently limited to three studies. In the Lung
Health Study II, a decline of 0.9% of baseline BMD was
found in COPD patients on inhaled corticosteroids as
compared to a stable BMD in the placebo group.10 More-
over, BMD remained stable one year after a pulmonary
rehabilitation program, as opposed to an improved BMD
after lung volume reduction surgery (LVRS).11 Finally, BMD
did not change during 3-year follow up in the TORCH study,
irrespective of treatment allocation.12
Summarizing, BMD generally remains stable in patients
with COPD over a period of 3 years. Nevertheless, in the
above mentioned studies the prevalence of vertebral frac-
tures was not assessed, while an increase of prevalence of
vertebral fractures with 12% was found during 4-year follow
up in patients with sarcoidosis.13 Therefore, observational
studies including local DXA scans and X-ray of the lumbar
spine will extent our current knowledge on the prevalence
and incidence of osteoporosis in patients with COPD.
Various determinants of osteoporosis have been identi-
fied in numerous cross-sectional studies.4,8 Moreover,
improvements in BMD following LVRS were associated with
a decline in residual volume (RV), an increase in diffusing
capacity for carbon monoxide, an increase in lean body
mass, a decrease in bone alkaline phosphatase, a decrease
in b-crosslaps and a decrease in methylprednisolone.11
Furthermore, a small but accelerated 3-year decline in
BMD has been suggested following the use of inhaled
corticosteroids compared to placebo in patients with
COPD,10 which was not corroborated by others.12 Conse-
quently, determinants of the progression of osteoporosis in
patients with COPD are partially recognized and warrant
further investigation.The aim of this study was twofold: (1) to determine
changes in BMD and number of vertebral fractures during 3-
year follow up in patients with COPD; and (2) to identify
possible baseline risk factors for the development of oste-
oporosis in these COPD patients.Methods
COPD patients were recruited from the outpatient pulmo-
nary clinic of the Catharina Hospital in Eindhoven, The
Netherlands from May 2005 until December 2005. Diagnosis
of COPD was made according to the American Thoracic
Society (ATS) Guidelines14 and classified according to the
Global Strategy for the Diagnosis, Management, and
Prevention of COPD (GOLD) guidelines.1 Patients were
clinically stable, defined as not treated for an acute COPD
exacerbation in the previous 6 months. Informed consent
was obtained from all patients and the study was approved
by the internal review board of the Catharina Hospital
Eindhoven. Some of the baseline data were used in
a previous publication.8
Inclusion criteria were: age >18 years, COPD according
to the ATS and classified according to the GOLD guidelines,
and written informed consent.
Medical history, medication use and smoking status were
assessed with a questionnaire and by reviewing the medical
charts. To report medical history the Charlson co-morbitity
index was used.15 To assess dyspnoea the Medical Research
Counsil (MRC) dyspnoea score was used (see Online data
supplement).
Height and weight were assessed and body mass index
(BMI) was calculated and defined as low (<21 kg/m2),
normal (21e25 kg/m2), overweight (>25e30 kg/m2) and
obese (>30 kg/m2). Bio-impedance analysis was performed
using the BODYSTAT 1500 medical, single frequency
(Xitron Technologies) and FFMI was defined as depleted
(men <16 kg/m2 and women <15 kg/m2) or normal.
Lung function parameters were assessed using the
Jaeger MASTERLAB BODY (VIASYS Healthcare). The
forced expiratory volume in the first second (FEV1) and
the forced vital capacity (FVC) were measured and
FEV1/FVC was calculated. A 6 min walking test was per-
formed according to the ATS guidelines.16 BMD was
assessed at the femoral neck and trochanter of the hip
and at the lumbar spine using a Delphi upgraded to
Discovery W (S/N 70991) DXA-scan. X-rays of the thoracic
and lumbar spine were perfomed using a digital Bucky
system (Digital Diagnost or H-Diagnost-Om65-CS64, Philips
Medical Systems). Vertebral fractures were assessed
according to Genant17 (see Online data supplement).
Osteoporosis was defined as a T-score 2.5 and/or
a vertebral fracture.6
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2008eDecember 2008). The 3-year BMD measurements
were obtained on the Hologic A discovery DXA scan (see
Online data supplement). Vertebral fractures were
assessed by instant vertebral assessment by means of
lateral DXA-scan (see Online data supplement). Hospital
admissions during the study were assessed. At baseline
venous blood samples were obtained to assess 25-
hydroxyvitamin D3 (25-OH-D3) levels. Vitamin D deficiency
was defined as 25-OH-D3 <50 nmol/L.18,19
Statistical analyses
Discrete variables were compared with Chi-square test and
presented as percentages. Continuous variables were
compared with students t-test and presented as mean -
 standard error of mean (SEM). Variables at baseline and
follow up were compared with paired sample t-test,
McNemar and Wilcoxon tests for continue, nominal and
ordinal variables, respectively.
Patients without osteoporosis at baseline were divided
into two subgroups: without- and with osteoporosis at 3-
year follow up. Their baseline variables were compared
using independent sample t-test and chi-square tests.
Univariate binary logistic regression analysis was per-
formed. Dependent variable was osteoporosis at follow up.
Baseline variables were used as covariates. If significant at
the p< 0.05 level variables were included in the multivar-
iate analysis. Odds ratio (OR) with 95% confidence intervals
(CI) are reported. A p-value <0.05 was used to indicate
statistical significance. All statistical analyses were per-
formed using Statistical Package for Social Sciences (SPSS)
version 16.0.Results
Of the 133 patients investigated in 2005, 90 patients (68%)
were re-assessed after 3 years. Of the 43 patients not
included in the follow up 16 died and 27 were unable or
unwilling to be re-assessed. There were no significant
differences in gender, age, body composition and GOLD
stage between patients that were re-assessed, and those
who were lost to follow up (see Online data supplement for
details). Patients lost to follow up had a significantly higher
prevalence of osteoporosis as compared to the studied
group (67% versus 47% pZ 0.025).
Baseline characteristics
The patients who were assessed at baseline and 3 years
later, generally were elderly patients with moderate to
very severe COPD (Table 1). A majority of these patients
were overweight and had a poor functional exercise
capacity. Forty patients (44%) reported 1 or more co-
morbidities on the Charlson co-morbidity index, while 28
patients (32%) had a vitamin D deficiency. Moreover, 42
patients (47%) showed osteoporosis based on DXA and X-
spine, while only 9 osteoporotic patients (21%) received
physician-prescribed bone medication. In another 24
patients of this group bone medication was newly started(57%), while the remaining 9 osteoporotic patients refused
any bone medication (22%).
Three-year follow up data
The mean FEV1 (% of predicted) decreased significantly
compared to baseline (Table 1). Consequently, significantly
more patients showed a higher GOLD-score: 11% more
patients with GOLD IV. Moreover, body weight remained
stable while the 6MWD decreased significantly compared to
baseline with a mean 37 m over 3 years (Table 1).
Prevalence of osteoporosis increased from 47% at base-
line to 61% at 3-year follow up. Of the 48 patients who did
not show osteoporosis at baseline, 16 patients (33%)
developed osteoporosis during 3-year follow up. Thirteen of
these new cases (81%) could be identified by X-spine, while
only three were exclusively identified by DXA (Fig. 1a).
Forty-two patients had osteoporosis at baseline. In this
group only 3 patients (7%) did not meet the criteria for
osteoporosis at follow up. On the DXA scan these 3 patients
were classified as osteopenic (T-score between 1 and
2.5) (Fig. 1b).
Of the 24 patients we prescribed bone medication at
baseline only 13 patients continued to use this medication
for 3 years. Both patients that used their medication and
patients that discontinued showed a significant increase in
vertebral fractures and BMD of the lumbar spine and a non-
significant decrease in BMD of the collum and trochanter
(see Online data supplement). There was no significant
difference when comparing change in BMD and change in
vertebral fractures between patients with and without
continuing to use their bone medication (see Online data
supplement).
Newly diagnosed osteoporosis
Patients without osteoporosis at baseline (nZ 48) were
divided into a group with (nZ 16) or without (nZ 32)
osteoporosis at 3-year follow up (Table 2).
At baseline, gender distribution and mean age were
comparable between groups. However, patients with oste-
oporosis at follow up had more pack years at baseline as
compared to patients without osteoporosis at follow up. In
addition, these patients had a lower T-score at the
trochanter and were more frequently vitamin D-deficient.
Patients who developed osteoporosis during 3-year
follow up showed a significant decrease in FEV1, whereas
lung function of patients without osteoporosis at follow up
remained stable: delta FEV1 8 versus 2% of predicted,
respectively (pZ 0.041). Other changes over 3 years were
not significantly different between groups.
Univariate and multivariate logistic regression
analyses
Results of univariate logistic regression analysis with oste-
oporosis at 3 years as dependent variable are shown in
Fig. 2. More pack years and the presence of vitamin D
deficiency increased the risk of developing osteoporosis in
3 years, whereas a higher T-score at the trochanter
decreased this risk (Fig. 2). Multivariate analysis showed
Table 1 Patients characteristics at baseline and follow up.
Baseline Follow up p-Value
Age, years (range) 68.7 0.9 (50 e88) 71.7 0.9 (53-91) NA
Male/Female, % 60/40 60/40 NA
FEV1, % of predicted 63.4 1.9 59.5 2.1 0.001
RV%TLC, % 51.9 1.1 53.4 1.0 0.050
GOLD
I, % 14 11
II, % 60 49 <0.001
III, % 19 22
IV, % 7 18
BMI, kg/m2 26.8 0.5 26.5 0.5 0.135
Normal, % 22 28
Low, % 8 9 0.495
Overweight, % 48 45
Obese, % 22 18
FFMI, males/females, kg/m2 17.7 0.3/15.9 0.3 18.2 0.3/16.1 0.4 0.002/0.214
Low, % 22 14 0.125
6MWD, meters 369 12 332 12 <0.001
Smoking
Ex-smokers, % 71 66 <0.001
Pack years 35.7 2.5 38.2 3.7 <0.001
Corticosteroids
Oral (chronic), % 12 11 1.000
Inhaled, % 67 66 0.791
Vitamin D deficiency, % 32 NA
Bone medication, % 14 41 <0.001
Osteoporosis, % 47 61 0.004
DXA alone, % 22 22 1.000
X-spine alone, % 32 52 <0.001
Osteopenia, % 48 50 <0.001
T-score
LS, g/cm2 0.8 0.2 0.6 0.2 <0.001
Femoral neck, g/cm2 1.3 0.1 1.5 0.1 <0.001
Trochanter, g/cm2 0.5 0.1 0.8 0.1 <0.001
Number of fractures
Thoracic spine 0.4 0.09 0.80 0.13 <0.001
Lumbar spine 0.10 0.04 0.16 0.05 0.025
Total 0.51 0.10 0.96 0.14 <0.001
Charlson score 1.68 0.10 2.03 0.12 <0.001
MRC dyspnoe scale 1.66 0.13 1.78 0.15 0.284
0, % 19 20
1, % 28 22 0.302
2, % 30 30
3, % 15 15
4, % 8 13
Results are presented as mean standard error of mean unless otherwise indicated.
FEV1, forced expiratory volume in the first second; RV%TLC, residual volume as percentage of the total lung capacity; GOLD, classifi-
cation of disease severity in four stages; BMI, body mass index; FFMI, fat free mass index; 6MWD, 6 minutes walking distance; NA, not
applicable; T-score, measured bone mineral density compared to the bone mineral density of the young gender matched population
expressed in standard deviation. MRC, Medical Research Council.
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Figure 1 (a) Bone status at baseline and follow up for
patients without osteoporosis at baseline. (b) Bone status at
baseline and follow up for patients with osteoporosis at
baseline.
Progression of osteoporosis in COPD 865that vitamin D deficiency and T-score at the trochanter
kept their significance independently of each other and of
the number of pack years smoked (Table 3a). Moreover,
osteopenia at the trochanter at baseline independently
increased the odds ratio for osteoporosis at follow up
(Table 3b).
Discussion
Our study is the first longitudinal study in COPD patients
diagnosing osteoporosis based on both DXA-scan and X-
spine. Prevalence of osteoporosis increased from 47% to
61% in a period of 3 years mostly due to an increase in
vertebral fractures. Vitamin D deficiency at baseline and
lower T-score at the trochanter were independent risk
factors for the development of osteoporosis during 3-year
follow up in patients with COPD.
Progression of osteoporosis
The significant increase in prevalence of osteoporosis in
COPD patients over a period of 3 years demonstrated in our
study is in contrast with the results of Ferguson et al.12 This
observation is probably due to the fact that in the latter
study results were based exclusively on DXA-scan data.
Indeed, the increase in prevalence of osteoporosis in our
study could mostly be contributed to an increase in verte-
bral fractures over time. This observation is in concordance
with the study of Heijckman et al. who also encountered anincreased prevalence of vertebral deformities (from 20% to
32%) despite an unchanged BMD after 4 years in patients
with sarcoidosis.13 Therefore, in patients with chronic
inflammatory disease like sarcoidosis and COPD the
increase in prevalence of osteoporosis is most likely due to
deterioration of the microarchitecture, without a signifi-
cant impact on bone mineral density. Indeed, chronic
inflammation leads to the production of cytokines,20,21
stimulating bone turnover, which is associated with an
increased fracture risk due to increased bone fragility.22
Indeed, in COPD patients evidence of low-grade systemic
inflammation had been found.23 However, this systemic
inflammation is very heterogeneous with different levels of
increased cytokines, acute phase proteins and other
circulating cells identified in various studies.23e25 Micro-
architectural changes can be non-invasively assessed by
microcomputed tomography which seems to correlate well
with histology of bone biopsies, which is the gold stan-
dard.26 Indeed, in osteoporosis research altered micro-
architecture is now considered an important component of
osteoporosis.27 Studies investigating this deteriorated
microarchitecture and inflammation markers in COPD
patients are warranted to further clarify the influence of
inflammation on bone status.
Especially in COPD patients it is important to diagnose
and to prevent vertebral fractures since they are known to
deteriorate pulmonary function.28 Indeed, kyphoplasty has
been shown to partially improve pulmonary function in
patients with a vertebral fracture.29 Currently, no other
longitudinal studies in COPD patients exist investigating the
prevalence of osteoporosis based on DXA-scan and X-spine.
However, the awareness that vertebral fractures are
common in COPD patients and that these fractures should
be assessed in diagnosing osteoporosis is rising.5,9,30,31
Because only a small group of patients used bone
medication during the 3 years, no conclusions about the
effect of this medication in COPD patient can be drawn.
More (randomized) follow up studies including more COPD
patients are warranted.Risk factors for osteoporosis in COPD
In the current sample of patients with COPD, vitamin D
deficiency and lower T-score at the trochanter were inde-
pendent risk factors for the development of osteoporosis
during 3-year follow up.
Vitamin D deficiency induces osteoporosis.18 Indeed,
prevalence of low vitamin D levels in postmenopausal
women with osteoporosis was found to be high.32 Vitamin D
intake in COPD patients was shown to be below the rec-
ommended intake.33,34 Vitamin D deficiency was found to
correlate with FEV1.
35 Moreover, Førli et al. found an
association between vitamin D deficiency and low T-scores
at the femoral neck in underweight candidates for lung
transplantation.36 However, they did not assess vertebral
fractures. Although we only investigated a moderate-size
group of patients with COPD, the high prevalence of
vitamin D deficiency (32%) and the fact that decreased
vitamin D levels independently increases the risk of osteo-
porosis 7.5-fold seems clinically relevant. However, as the
precise interrelationships between vitamin D deficiency,
Table 2 Patients without osteoporosis at baseline (nZ 48) baseline and follow up data after stratification for no-osteoporosis
versus osteoporosis after follow up. The bold values represents the significance of p < 0.005.
No osteoporosis baseline;
no osteoporosis follow up (nZ 32)
No osteoporosis baseline;
osteoporosis follow up (nZ 16)
p-Value
baseline both
groupsBaseline Follow up p-Value Baseline Follow up p-Value
Age, years 67.6 1.7 68.2 1.6 0.826
Male/female, % 63/38 63/38 1.000
FEV1, % of predicted 64.3 3.4 62.8 3.8 0.462 70.1 0.4 62.1 4.0 <0.0001 0.422
RV%TLC, % 61.0 1.9 51.4 1.6 0.767 48.6 1.9 50.4 2.0 0.157 0.658
GOLD
I, % 19 13 0.071 19 6 0.025 0.554
II, % 56 53 69 69
III, % 22 17 6 13
IV, % 3 17 6 12
BMI, kg/m2 27.6 0.8 27.4 0.9 0.653 28.1 1.2 27.2 1.3 0.055 0.719
Normal, % 16 13 0.357 25 25 0.705 0.673
Low, % 6 9 0 6
Overweight, % 50 59 50 44
Obese, % 28 19 25 25
FFMI
Males, kg/m2 17.4 0.4 18.0 0.4 0.074 18.2 0.7 18.8 0.8 0.136 0.362
Females, kg/m2 16.4 0.6 17.2 0.8 0.137 16.5 0.4 16.3 0.7 0.743 0.824
Low, % 25 10 0.125 7 6 1.000 0.141
6MWD, meters 373 16 321 17 <0.0001 388 18 361 17 0.030 0.696
Smoking
Ex-smokers, % 75 70 0.500 69 57 1.000 0.646
Pack years 29.5 4.3 30.0 4.4 0.023 43.0 5.1 44.1 5.1 0.029 0.034
Corticosteroids
Oral, % 13 6 0.500 6 0 1.000 0.504
Cummulative, mg 1440 421 1913 927 0.653 2632 1259 2770 668 0.264 0.269




Bone medication, % 3 6 0.655 19 25 1.000 0.065
Osteoporosis, % 0 0 0 100 <0.0001 1.000
DXA, % 0 0 1.000 0 31 0.063 1.000
X-spine, % 0 0 1.000 0 81 <0.0001 1.000
T-score
LS 0.2 0.3 0.1 0.3 0.380 0.6 0.3 0.6 0.3 0.960 0.434
Femoral neck 0.9 0.2 1.1 0.2 0.007 1.3 0.2 1.7 0.2 <0.0001 0.133
Trochanter 0.1 0.2 0.2 0.2 <0.0001 0.6 0.2 0.9 0.3 0.010 0.019
Number of fractures
Thoracic spine 0 0 0 1.06 0.004 1.000
Lumbar spine 0 0 0 0.19 0.083 1.000
Total 0 0 0 1.25 0.001 1.000
Charlson score 1.56 0.18 1.81 0.20 0.030 1.56 0.20 2.06 0.28 0.027 1.000
MRC-scale 1.59 0.18 1.68 0.23 0.823 1.63 0.30 1.85 0.37 0.367 0.925
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Table 2 (continued )
No osteoporosis baseline;
no osteoporosis follow up (nZ 32)
No osteoporosis baseline;
osteoporosis follow up (nZ 16) p-Value
baseline both
groupsBaseline Follow up p-Value Baseline Follow up p-Value
Hospital admission
3 yrs
Pulmonary problem, % NA 7 NA 15 NA
Other, % NA 28 NA 7 NA
Results are presented as mean standard error of mean unless otherwise indicated. Osteoporosis is based on DXA-scan and X-spine.
FEV1, forced expiratory volume in the first second; RV%TLC, residual volume as percentage of the total lung capacity; GOLD, classifi-
cation of disease severity in four stages; BMI, body mass index; FFMI, fat free mass index; 6MWD, 6 minutes walking distance; T-score,
measured bone mineral density compared to the bone mineral density of the young gender matched population expressed in standard
deviation; MRC-scale, Medical Research Councel Dyspnoea scale; NA, not applicable.
Progression of osteoporosis in COPD 867osteoporosis and COPD is still not clarified, this should be
investigated further. The awareness of (chest) physicians
regarding the importance of vitamin D deficiency should be
raised, not only because of the important effect of vitamin
D on bone status, but also because of its possible non-
calcemic effects (e.g. inflammation, muscular dysfunction
and co-morbidities) in COPD patients.37 Moreover, Kuchuk
et al. found in postmenopausal women with osteoporosis
a positive relationship between vitamin D levels with
a threshold at 50 nmol/L and BMD at the trochanter.32
Combined with the fact that we found both lower T-
scores at the trochanter and vitamin D deficiency to be
independent predictors of osteoporosis, theoretically both
risk factors could be reduced by vitamin DFigure 2 Forrest plot of the results of univariate regression
analysis with osteoporosis at 3 years as dependent variable.
Univariate regression analyses were done in patients without
osteoporosis at baseline (nZ 48) with osteoporosis at follow up
as dependent variable. Results are presented as odds ratio’s
and 95% confidence intervals on a logarithmic scale. BMI, body
mass index; FFMI, fat free mass index; 6MWD, 6 minutes
walking distance; FEV1, forced expiratory volume in the first
second; GOLD, classification of chronic obstructive pulmonary
disease in four stages; def, deficiency; LS, lumbar spine; FN,
femoral neck.supplementation. In the current study we could not eval-
uate the effect of vitamin D supplementation, because only
three patients used the prescribed vitamin D during the 3
years of follow up. Randomized, placebo controlled, clin-
ical trials are needed to investigate the influence of vitamin
D supplementation on bone status and on non-calcemic
effects in COPD patients.
A lower baseline T-score at the level of the trochanter
was also independently increasing the risk of osteoporosis.
In a 4-year follow up study in patients with sarcoidosis, the
T-score at the level of the femoral neck was an indepen-
dent risk factor for new and/or progressive vertebral frac-
tures.13 This difference in T-scores at the trochanter and
femoral neck area respectively, as significant risk factor,
could be due to the fact that patients with COPD and
sarcoidosis were investigated resulting in different patient
characteristics. However, in both studies T-score at the hip
proved to be a significant risk factor as opposed to T-scoreTable 3 Multivariate analysis. The bold values represents
the significance of p < 0.005.
OR 95% CI p-Value
a
Pack years 1.032 0.994e1.072 0.099
T-score trochanter 0.0343 0.129e0.911 0.032
Vitamin D deficiencya 7.487 1.175e47.705 0.033
b
Pack years 1.038 0.998e1.080 0.061
Osteopenia trochanterb 9.916 1.511e65.050 0.017
Vitamin D deficiencya 7.931 1.269e49.551 0.027
Only patients without osteoporosis at baseline were included
(nZ 48). Osteoporosis at 3 years was used as dependent vari-
able. Only variables significant at p< 0.05 in univariate
regression analysis were included. Included variables are
therefore corrected for pack years, vitamin D deficiency and T-
score at the trochanter (all at baseline).
a As compared to normal vitamin D (25 OH D3 lev-
els 50 ng/L).
b As compared to a normal BMD at the trochanter (T-
score1).
868 L. Graat-Verboom et al.at the lumbar spine. A lower T-score at the lumbar spine did
not increase the risk of osteoporosis in the current study,
although a trend was found. Indeed, BMD at the lumbar
spine could theoretically be erroneously elevated due to
vertebral deformity (<20% reduction in height), thereby
condensing the bone structure and elevating bone density.
Interestingly, patients who developed osteoporosis over
a 3-year period of time in the present study had a higher
proportion of vitamin D deficient patients at baseline and
showed a greater deterioration in their FEV1 as compared to
those who did not develop osteoporosis (Table 2). More-
over, osteoporosis is highly prevalent in patients with
COPD,4 raising the question whether this is the result of co-
morbidity, some metabolic syndrome or the result of
common genetic susceptibility. Indeed, the ADAM19 gene
may play a role in the development of COPD38 as well as
osteoporosis.39 Moreover, a common genetic susceptibility
for vitamin D deficiency and COPD was found by Janssens
and colleagues.40 In their study they found that vitamin D
levels were reduced by 25% in homozygous carriers of the
rs7041 T allele and that these carriers exhibited an
increased risk for COPD. Moreover, since there is an
established link between vitamin D levels and FEV1,
35 there
could be an interrelationship between vitamin D levels,
more rapid decline of FEV1 and osteoporosis in COPD. One
might speculate that patients who had a rapid decline in
their FEV1 might were less active because of this deterio-
rating lung function. Because of this inactivity they might
also be more prone to developing osteoporosis. However, to
date, no data exist in the English-language literature on the
interaction between the change in FEV1 and change in
physical activity levels in patients with COPD. Nevertheless,
physical inactivity also occurs in about 75% of the patients
with GOLD stage II,41,42 or following lung transplantation.43
These data suggest that the cross-sectional relationship
between the degree of airflow limitation and the degree of
daily physical activity is limited and most probably worse
when this relationship is studied using the changes over
time. Finally, the increase of osteoporosis in the current
study was mostly due to an increase in vertebral fractures,
and not a decline in BMD. Whether inactivity also causes an
increase in vertebral fractures remains to be determined.
In the general population smoking is one of the risk
factors for osteoporosis.6 Indeed, we found that more pack
years of smoking was a significant risk factor for osteopo-
rosis in the current study. However, significance dis-
appeared in multivariate analysis.Methodological limitations
Some methodological limitations should be mentioned.
Primarily, the group of patients used to determine risk
factors for osteoporosis had a moderate size (nZ 48).
Consequently, results from regression analysis should be
interpreted with caution. However, the current results imply
an important role of baseline vitamin D and low T-score at
the hip, which seems very reasonable. Therefore, the need
to focus on vitamin D deficiency in COPD patients should
once more be stressed.37 Secondly, more follow up studies in
COPD patients with osteoporosis based on the combination
of DXA-scan and vertebral fractures are needed to confirmour preliminary results. Thirdly, vitamin D values were
obtained from May until December. Therefore, the seasons
could have influenced the levels of vitamin D and conse-
quently, the prevalence of vitamin D deficiency. However,
no significant difference of vitamin D levels or vitamin D
deficiency between months were encountered (see Online
data supplement). Fourthly, different DXA-scans were used
at baseline and follow up. However, the same standard
operation procedures were used and both scans were cali-
brated using a phantom at a daily base. In addition, both
DXA-scans were compared with the same phantom on the
same day and the difference in mean BMD was less than 1%
(see Online data supplement). Therefore, measurements
performed on both DXA-scans are comparable and differ-
ences are due to changing BMD. Fifthly, morphometry using
spine radiographs and DXA were performed at baseline and
at follow up. A limitation of morphometry by DXA is that
there is a lower sensitivity for milder fractures.44 Therefore,
the vertebral fractures at follow up could be an underesti-
mation. Sixthly, no physical activity assessment was done.
However, we did include the six minutes walking distance
which might be used as a surrogate marker for physical
activity, especially in COPD patients with a walking distance
of about 400 m.45 Furthermore MRC dyspnoea score did not
change significantly during the course of this study. In case
patients might become less active because of a worsening
lung function, one might expect that the MRC score would
also have increased. Finally, a healthy age-matched control
group was lacking. Therefore, it remains currently unknown
whether and to what extent the progression of osteoporosis
is COPD specific. However, in postmenopausal women with
osteoporosis 7.1% had a new vertebral fracture after 3 years
of treatment with placebo.46 Compared to the 20% of
patients with new vertebral fractures in the current study
progression of osteoporosis could be COPD specific. Then
again, progression of osteoporosis has also been found in
HIV-infected patients, patients with rheumatic diseases and
patients with sarcoidosis.13,47,48Clinical relevance
One of the strengths of our study is the collection of follow
up data after a period of 3 years. Moreover, we diagnosed
osteoporosis with DXA-scan and X-spine combined. Finally,
we included patients in all GOLD stages, whereas most other
studies did not include patients with GOLD I COPD.5,9,12,36
Because of the high prevalence of osteoporosis in COPD
patients we advise physicians to evaluate all COPD patients
for osteoporosis. This evaluation should be performed by
DXA-scan and X-spine, because osteoporosis will be missed
in a significant proportion of patients when assessing BMD
exclusively without including the presence of vertebral
fractures. In addition, we advise physicians to determine
vitamin D levels in all COPD patients and to start supple-
mentation in case of deficiency. This approach has also
been suggested by others.49 Whether this prevents patients
to develop osteoporosis warrants further research. Finally,
follow up can best be performed by assessing vertebral
fractures once a year. In patients with vitamin D deficiency
and/or osteopenia at the level of the hip BMD should be
assessed every 3 years.
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